ARDX Key Statistics, Chart & Performance
The current stock price of ARDX is 6.15 USD. In the past month the price increased by 6.59%. In the past year, price increased by 23.74%.
ARDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About ARDX
Company Profile
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Waltham, Massachusetts and currently employs 395 full-time employees. The company went IPO on 2014-06-19. The firm has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
Company Info
ARDELYX INC
400 Fifth Avenue, Suite 210
Waltham MASSACHUSETTS 94555 US
CEO: Michael Raab
Employees: 395
Phone: 15107451700
ARDELYX INC / ARDX FAQ
What does ARDELYX INC do?
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Waltham, Massachusetts and currently employs 395 full-time employees. The company went IPO on 2014-06-19. The firm has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
Can you provide the latest stock price for ARDELYX INC?
The current stock price of ARDX is 6.15 USD. The price increased by 5.49% in the last trading session.
Does ARDELYX INC pay dividends?
ARDX does not pay a dividend.
What is the ChartMill rating of ARDELYX INC stock?
ARDX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting ARDX stock to perform?
17 analysts have analysed ARDX and the average price target is 11.93 USD. This implies a price increase of 94.05% is expected in the next year compared to the current price of 6.15.
Should I buy ARDX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ARDX.
What is the employee count for ARDX stock?
ARDELYX INC (ARDX) currently has 395 employees.
ARDX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ARDX. When comparing the yearly performance of all stocks, ARDX is one of the better performing stocks in the market, outperforming 85.43% of all stocks.
ARDX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARDX. Both the profitability and financial health of ARDX have multiple concerns.
ARDX Financial Highlights
Over the last trailing twelve months ARDX reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 24.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.63% | ||
| ROE | -36.65% | ||
| Debt/Equity | 1.31 |
ARDX Forecast & Estimates
17 analysts have analysed ARDX and the average price target is 11.93 USD. This implies a price increase of 94.05% is expected in the next year compared to the current price of 6.15.
For the next year, analysts expect an EPS growth of -47.06% and a revenue growth 22.2% for ARDX